Key Takeaways:
US patients will pay more for generic medicines after President Donald Trump's plan to impose a 100% tariff on imported generics takes effect in August 2026, the chief executive of Indian drugmaker Dr Reddy's Laboratories warned.
US President Donald Trump's plan to impose a 100% tariff on imported generic drugs will raise medicine costs for American patients, the chief executive of Indian pharmaceutical company Dr Reddy's Laboratories warned, as the policy threatens to upend a supply chain that delivers nearly half of America's generic medicines.
"Manufacturing generic drugs in India significantly lowers the cost of medicine for the United States, and any tariff on these imports will ultimately be passed on to patients," the chief executive of Dr Reddy's Laboratories said.
The tariffs, announced by Trump on his Truth Social platform, will keep generic drug imports at zero percent until Aug. 1, 2026, then rise to 100% for one year before climbing to 200% thereafter. India supplies about 47% of generic drugs consumed in the US by volume, representing $9.7 billion in exports — 37.7% of the country's total pharmaceutical shipments of $25.8 billion in 2025, according to the Global Trade Research Initiative.
The two-year window offers Indian drugmakers time to adjust, but building US manufacturing capacity at scale with regulatory approvals may take longer than the grace period allows, industry executives said. The policy could reshape a decades-old supply chain where Indian generics sell at seven to 10 times less than branded alternatives, potentially benefiting US-based manufacturers while squeezing Indian exporters.
Citi analyst Veronika Dubajova said the policy appeared likely to favor manufacturers that already produce most of their US-bound medicines domestically. Hikma Pharmaceuticals, the London-listed drugmaker, manufactures more than 75% of its US sales volumes in the country, including 90% to 95% of non-injectable products and about 60% of injectables. Fresenius Medical Care's Kabi division produces more than 70% of its US volumes domestically, with high-value active ingredients sourced in America for products manufactured elsewhere.
The previous round of US tariffs on branded and patented medicines, announced in September 2025 at 100%, was followed by an additional 100% levy on selected branded drugs and raw materials in April 2026. After that escalation, the S&P 500 Health Care sector fell 3.2% over the following two weeks while the NYSE Arca Pharmaceutical Index dropped 4.1%, according to exchange data.
Thomas V Abraham, research analyst at Mirae Asset Sharekhan, said most large Indian pharma companies already have some manufacturing presence in the US, either organically or through acquisitions, and the two-year timeline provides enough room to comply. "Investors could turn risk averse in the near term as they await clarity," he said.
Even with a 100% tariff, many Indian generic medicines could remain cheaper than their branded counterparts, which are priced seven to 10 times higher, the GTRI report noted. The additional cost could also be passed on to US health-care providers, insurers and patients, reducing the direct impact on Indian exporters. However, high-value generics and branded generics would become more viable for US-based production.
The policy's long implementation period and sparse details mean the financial impact remains difficult to quantify. Fresenius Medical Care reports second-quarter results on Aug. 5, followed by Hikma's first-half figures on Aug. 6, which may offer early signals on how the tariff threat is shaping investment decisions. India, which relies on China for a significant portion of active pharmaceutical ingredients, faces additional supply chain challenges in shifting production to the US.
This article is for informational purposes only and does not constitute investment advice.
